Merck & Co, INC

Merck & Co., Inc. announced second-quarter 2026 financial results, highlighting $16.6 billion in worldwide sales with 5% growth, driven by oncology and animal health, alongside key regulatory approvals and clinical milestones.

Merck & Co. shareholders re-elected all director nominees and ratified the appointment of the company's independent auditor at the 2026 Annual Meeting.

Merck & Co., Inc. has successfully closed an underwritten public offering of $6 billion in aggregate principal amount of senior notes across seven different series.

Merck & Co. announced first-quarter 2026 financial results, reporting $16.3 billion in worldwide sales and raising its full-year financial outlook.

Merck announced robust fourth-quarter and full-year 2025 financial results, driven by oncology and new product launches, while outlining a strategic 2026 outlook impacted by a major acquisition charge.

Merck & Co., Inc. successfully closed an underwritten public offering of $8 billion in various senior notes with maturities ranging from 2029 to 2065.

Merck & Co. reported a net loss for Q1 2026, impacted by significant acquisition charges, though operational sales showed a 5% increase driven by oncology and animal health segments.

Merck reported a significant increase in net income and EPS for Q3 2025, driven by strong performance in its oncology and cardiovascular franchises, despite declines in vaccines and virology.

Merck reports a significant drop in second-quarter net income and sales, driven by vaccine declines and increased restructuring costs, despite strong oncology growth and new product launches.

Merck & Co.'s Q1 2025 results show a slight sales decrease due to vaccine and virology declines, balanced by oncology and diabetes growth, with Keytruda remaining a key driver.

Merck & Co. announced its third-quarter 2024 results, marked by revenue growth driven by oncology and animal health, alongside significant acquisition charges and restructuring costs.

Merck & Co. reported a 7% increase in worldwide sales for the second quarter of 2024, driven by strong performance in its oncology and vaccine franchises.

Merck reports modest 2025 sales growth driven by oncology and animal health, while facing significant patent expirations and IRA pricing pressures on key products, alongside strategic acquisitions and pipeline advancements.

Merck & Co.'s 2024 annual report reveals robust sales growth driven by its oncology portfolio, particularly Keytruda, while also outlining challenges and strategic initiatives for the future.

Merck & Co. has filed an amendment to its annual report to correct the date of the annual shareholder meeting from May 18, 2024 to May 28, 2024.

Merck & Co.'s 2023 10-K filing details a year of growth driven by oncology and vaccines, alongside strategic investments and pipeline advancements.

Christine E. Seidman, a Director at Merck & Co., Inc., has reported transactions involving common stock and phantom stock units.

Merck & Co., Inc. Director Surendralal L. Karsanbhai reports a transaction involving phantom stock units settled in cash upon termination of service.

Mary Ellen Coe, a Director at Merck & Co., Inc., has reported transactions involving phantom stock units and common stock.

Merck & Co., Inc. director Kathy J. Warden acquired 1,853.0997 phantom stock units, settled in cash upon termination of service.

Merck & Co., Inc. director Surendralal L. Karsanbhai reported a transaction involving phantom stock units.

Mary Ellen Coe, a Director at Merck & Co., Inc., reported transactions involving phantom stock units and common stock.

Merck & Co., Inc. has issued its 2026 Proxy Statement detailing the agenda for its Annual Meeting of Shareholders, including the election of directors, advisory vote on executive compensation, and ratification of its auditor.

Merck & Co. announces its 2025 Annual Meeting of Shareholders to be held virtually on May 27, 2025, outlining key proposals for voting.

Merck & Co. announces its 2025 Annual Meeting of Shareholders, highlighting advancements in medicines and vaccines, strategic priorities, and pipeline expansion.

Merck & Co. has scheduled its 2024 Annual Meeting for May 28, 2024, and is seeking shareholder votes on director elections, executive compensation, auditor ratification, and various shareholder proposals.

Merck & Co.'s proxy statement details the company's strategy, governance, and executive compensation for the upcoming annual meeting.

Merck & Co., Inc. has filed its quarterly 13F holdings report, detailing significant investments in various biotechnology companies as of March 31, 2026.

Merck & Co. Inc. disclosed its institutional equity holdings for Q3 2025, totaling over $228 million across 13 positions.

Merck & Co., Inc. disclosed its equity holdings for the second quarter of 2025, totaling over $215 million across 13 companies, primarily in the biotechnology and pharmaceutical sectors.

Merck & Co.'s latest 13F filing reveals its holdings as of March 31, 2025, totaling over $164 million across various biotech and pharmaceutical companies.

Merck & Co., Inc. reports its holdings for the quarter ended December 31, 2024, revealing significant investments in various biotechnology and pharmaceutical companies.

Vanguard Capital Management disclosed a beneficial ownership of 186,323,766 shares, representing 7.53% of Merck & Co.'s common stock as of March 31, 2026.

The Vanguard Group has reported 0% beneficial ownership of Merck & Co Inc common stock following an internal realignment on January 12, 2026.

The Vanguard Group has filed an amended Schedule 13G, disclosing a beneficial ownership of 10.02% in Merck & Co Inc's common stock as of February 28, 2025.

Merck & Co., through its indirect wholly-owned subsidiary Merck Global Health Innovation Fund, LLC, has reported a beneficial ownership of 19.96% in Evaxion Biotech A/S, comprising ordinary shares and warrants.